After finishing at $84.04 in the prior trading day, Medtronic Plc (NYSE: MDT) closed at $83.41, down -0.75%. In other words, the price has decreased by $+0.06 from its previous closing price. On the day, 6166381 shares were traded.
Ratios:
Our goal is to gain a better understanding of MDT by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.31 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 22.46. For the most recent quarter (mrq), Quick Ratio is recorded 1.71 and its Current Ratio is at 2.30. In the meantime, Its Debt-to-Equity ratio is 0.49 whereas as Long-Term Debt/Eq ratio is at 0.47.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on July 19, 2023, initiated with a Neutral rating and assigned the stock a target price of $90.
On June 30, 2023, CL King started tracking the stock assigning a Buy rating and target price of $106.
Morgan Stanley Upgraded its Equal-Weight to Overweight on May 30, 2023, while the target price for the stock was maintained at $104.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 21 ’24 when Salmon Sean sold 30,695 shares for $85.13 per share. The transaction valued at 2,613,055 led to the insider holds 48,289 shares of the business.
Wall Brett A. sold 4,997 shares of MDT for $410,603 on Dec 19 ’23. The EVP & Pres Neuroscience now owns 28,910 shares after completing the transaction at $82.17 per share. On Aug 23 ’23, another insider, Smith Gregory L, who serves as the EVP Global Ops & Supply Chain of the company, sold 10,000 shares for $83.84 each. As a result, the insider received 838,400 and left with 46,723 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MDT now has a Market Capitalization of 110.75B and an Enterprise Value of 127.61B. As of this moment, Medtronic’s Price-to-Earnings (P/E) ratio for their current fiscal year is 26.46, and their Forward P/E ratio for the next fiscal year is 15.30. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 7.60. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.43 while its Price-to-Book (P/B) ratio in mrq is 2.14. Its current Enterprise Value per Revenue stands at 3.95 whereas that against EBITDA is 14.32.
Stock Price History:
Over the past 52 weeks, MDT has reached a high of $92.02, while it has fallen to a 52-week low of $68.84. The 50-Day Moving Average of the stock is 85.48, while the 200-Day Moving Average is calculated to be 82.07.
Shares Statistics:
The stock has traded on average 6.12M shares per day over the past 3-months and 6.76M shares per day over the last 10 days, according to various share statistics. A total of 1.33B shares are outstanding, with a floating share count of 1.33B. Insiders hold about 0.07% of the company’s shares, while institutions hold 85.31% stake in the company. Shares short for MDT as of Feb 29, 2024 were 8.45M with a Short Ratio of 1.38, compared to 10.87M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.64% and a Short% of Float of 0.64%.
Dividends & Splits
In the trailing 12 months, MDT’s forward annual dividend rate was 2.75, compared to 3.44 this year. Against a Trailing Annual Dividend Yield of 3.30%, it implies a Forward Annual Dividend Yield of 3.31%. The stock’s 5-year Average Dividend Yield is 2.49. The current Payout Ratio is 96.47% for MDT, which recently paid a dividend on Apr 12, 2024 with an ex-dividend date of Mar 21, 2024. Stock splits for the company last occurred on Sep 27, 1999 when the company split stock in a 2:1 ratio.
Earnings Estimates
Its stock is currently analyzed by 27 different market analysts. On average, analysts expect EPS of $1.45 for the current quarter, with a high estimate of $1.46 and a low estimate of $1.44, while EPS last year was $1.57. The consensus estimate for the next quarter is $1.25, with high estimates of $1.3 and low estimates of $1.2.
Analysts are recommending an EPS of between $5.21 and $5.18 for the fiscal current year, implying an average EPS of $5.2. EPS for the following year is $5.45, with 30 analysts recommending between $5.53 and $5.33.
Revenue Estimates
25 analysts predict $8.44B in revenue for the current quarter. It ranges from a high estimate of $8.53B to a low estimate of $8.34B. As of the current estimate, Medtronic Plc’s year-ago sales were $8.54B, an estimated decrease of -1.20% from the year-ago figure.
A total of 31 analysts have provided revenue estimates for MDT’s current fiscal year. The highest revenue estimate was $32.38B, while the lowest revenue estimate was $32.12B, resulting in an average revenue estimate of $32.22B. In the same quarter a year ago, actual revenue was $31.23B, up 3.20% from the average estimate. Based on 31 analysts’ estimates, the company’s revenue will be $33.58B in the next fiscal year. The high estimate is $33.93B and the low estimate is $32.93B. The average revenue growth estimate for next year is up 4.20% from the average revenue estimate for this year.
